Investing in biotech stocks is a thrilling ride. These innovative businesses developing breakthrough drugs can generate enormous profits for investors but also destroy significant value if their investigational therapies fail to make it to market.The pandemic focused a lot of attention on the sector. The SDPR S&P Biotech ETF (NYSEARCA:XBI) soared 49% in 2020, outpacing the S&P 500 and the Nasdaq 100. But the exchange-traded fund has faced a more difficult road since. The ETF is down 30% as investor attentio ...